BR112022013160A2 - Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricos - Google Patents
Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricosInfo
- Publication number
- BR112022013160A2 BR112022013160A2 BR112022013160A BR112022013160A BR112022013160A2 BR 112022013160 A2 BR112022013160 A2 BR 112022013160A2 BR 112022013160 A BR112022013160 A BR 112022013160A BR 112022013160 A BR112022013160 A BR 112022013160A BR 112022013160 A2 BR112022013160 A2 BR 112022013160A2
- Authority
- BR
- Brazil
- Prior art keywords
- dextromethadone
- diseases
- neuropsychiatric disorders
- disease modifying
- modifying treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956839P | 2020-01-03 | 2020-01-03 | |
| US202062963874P | 2020-01-21 | 2020-01-21 | |
| US202062993188P | 2020-03-23 | 2020-03-23 | |
| US202063010391P | 2020-04-15 | 2020-04-15 | |
| US202063031785P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/067498 WO2021138443A1 (en) | 2020-01-03 | 2020-12-30 | Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013160A2 true BR112022013160A2 (pt) | 2022-11-08 |
Family
ID=76687448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013160A BR112022013160A2 (pt) | 2020-01-03 | 2020-12-30 | Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230017786A1 (https=) |
| EP (1) | EP4085044A4 (https=) |
| JP (2) | JP2023509484A (https=) |
| KR (1) | KR20220164470A (https=) |
| CN (1) | CN115397804A (https=) |
| AU (1) | AU2020419181A1 (https=) |
| BR (1) | BR112022013160A2 (https=) |
| CA (1) | CA3166254A1 (https=) |
| MX (1) | MX2022007768A (https=) |
| TW (1) | TW202140415A (https=) |
| UY (1) | UY39007A (https=) |
| WO (1) | WO2021138443A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119202724B (zh) * | 2024-09-25 | 2025-05-30 | 宁夏医科大学总医院 | 一种脓毒症心肌病诊断模型的构建方法及诊断系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1715843A1 (en) * | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US9468611B2 (en) * | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| EP2906202A4 (en) * | 2012-10-15 | 2016-04-27 | Isa Odidi | ORAL DRUG RELIEF FORMULATIONS |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
| EP3917619A4 (en) * | 2019-01-30 | 2022-10-26 | University of Padova | Structurally modified opioids for prevention and treatment of diseases and conditions |
-
2020
- 2020-12-30 KR KR1020227026586A patent/KR20220164470A/ko active Pending
- 2020-12-30 US US17/787,608 patent/US20230017786A1/en active Pending
- 2020-12-30 JP JP2022541634A patent/JP2023509484A/ja active Pending
- 2020-12-30 WO PCT/US2020/067498 patent/WO2021138443A1/en not_active Ceased
- 2020-12-30 BR BR112022013160A patent/BR112022013160A2/pt unknown
- 2020-12-30 MX MX2022007768A patent/MX2022007768A/es unknown
- 2020-12-30 EP EP20908770.9A patent/EP4085044A4/en active Pending
- 2020-12-30 AU AU2020419181A patent/AU2020419181A1/en active Pending
- 2020-12-30 CA CA3166254A patent/CA3166254A1/en active Pending
- 2020-12-30 CN CN202080097944.9A patent/CN115397804A/zh active Pending
-
2021
- 2021-01-04 TW TW110100157A patent/TW202140415A/zh unknown
- 2021-01-05 UY UY0001039007A patent/UY39007A/es unknown
-
2026
- 2026-01-05 JP JP2026000511A patent/JP2026062924A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023509484A (ja) | 2023-03-08 |
| US20230017786A1 (en) | 2023-01-19 |
| WO2021138443A1 (en) | 2021-07-08 |
| EP4085044A1 (en) | 2022-11-09 |
| MX2022007768A (es) | 2022-09-27 |
| UY39007A (es) | 2021-07-30 |
| KR20220164470A (ko) | 2022-12-13 |
| EP4085044A4 (en) | 2024-06-12 |
| CN115397804A (zh) | 2022-11-25 |
| CA3166254A1 (en) | 2021-07-08 |
| JP2026062924A (ja) | 2026-04-10 |
| TW202140415A (zh) | 2021-11-01 |
| AU2020419181A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017393A2 (pt) | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112018076114A2 (pt) | composições tópicas de apremilast | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| BR112022013554A2 (pt) | Métodos para tratar distúrbios do pênfigo | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112021021676A2 (pt) | Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2023011166A (es) | Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| EA202190966A1 (ru) | Пролекарства антагонистов cgrp | |
| BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
| CO2024011399A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto | |
| BR112022013160A2 (pt) | Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricos | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| BR112022009881A2 (pt) | Inibidores de caspase 6 e usos dos mesmos | |
| BR112018073410A2 (pt) | combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112022015869A2 (pt) | Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |